secwatch.observer — SEC 8-K summary
======================================

Issuer:     COGNITION THERAPEUTICS INC (CGTX)
CIK:        0001455365
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001104659-24-057711
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cognition Therapeutics Q1 net loss $9.2M; cash runway through Q2 2025; SHINE data mid-2024
--------------------------------------------------------------------------------

- Net loss of $9.2M ($0.27/share) vs $6.2M ($0.21/share) in Q1 2023.
- Cash and equivalents $34.7M plus $62.3M in NIA grant funds; sufficient through Q2 2025.
- R&D expenses rose to $10.6M from $5.4M, driven by Phase 2 trial activities.
- Topline SHINE (Alzheimer's) results expected mid-2024; SHIMMER (DLB) enrolled 130 participants.
- Completed follow-on offering in March 2024, netting $11.9M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1455365/000110465924057711/0001104659-24-057711-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1455365/000110465924057711/tm2413335d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-057711

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer